TPD & Induced Proximity Summit Leaderboard
  • Friday, July 31, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 786

Author

Pharma Journalist 8969 posts 0 comments

60° Pharmaceuticals (60P) receives priority review designation for Malaria Drug

Feb 8, 2018
60 Degrees Pharmaceuticals (60P) received Priority Review Designation from the United States Food and Drug Administration (USFDA) for Tafenoquine (TQ) for prevention of malaria in…
Read More...

Concept Life Sciences expands GXP compliance

Feb 8, 2018
Concept Life Sciences announced the completion of the first phase of its GXP compliance plan, achieving GLP (good laboratory practice) accreditation of its Dundee site for in vitro …
Read More...

Novo Nordisk Launches Rebinyn in the United States for People with Hemophilia B

Feb 8, 2018
Novo Nordisk announced that Rebinyn, Coagulation Factor IX (Recombinant), GlycoPEGylated, is now available in the United States for the treatment of hemophilia B. Rebinyn is an…
Read More...

Sosei Provides an Update on Its Immuno-Oncology Clinical Program with AstraZeneca

Feb 8, 2018
Sosei Group Corporation announces that its immuno-oncology collaboration with AstraZeneca is progressing well. The first patient has been dosed in an expansion cohort in the Phase 1b…
Read More...

Selvita appoints Steffen Heeger as Chief Medical Officer

Feb 8, 2018
Selvita S.A. (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services, announced the…
Read More...

Major research project launched to crack aspirin’s anti-cancer properties

Feb 7, 2018
Cancer Research UK launches an international study to answer the final questions before aspirin could be recommended to reduce cancer risk. Studies have estimated that widespread…
Read More...

Roivant Sciences and ArQule enter into License Agreement for Derazantinib in China

Feb 7, 2018
Roivant Sciences and ArQule announced the initiation of a collaboration to pursue the development of derazantinib, a pan-FGFR (fibroblast growth factor receptor) inhibitor, in Greater…
Read More...

Xcovery initiates Phase 2 Clinical Trial for Ensartinib in Melanoma Patients with ALK Alternations

Feb 7, 2018
Xcovery announced the initiation of its Phase 2 clinical trial of ensartinib (X-396), the company’s lead anaplastic lymphoma kinase (ALK) drug candidate, in patients with advanced…
Read More...

Capricor receives FDA RMAT Designation for Duchenne Muscular Dystrophy Therapy

Feb 6, 2018
Capricor Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted CAP-1002, its lead investigational cell therapy for the treatment of Duchenne muscular…
Read More...

FDA Clears Oricula Therapeutics Investigational New Drug Application for Clinical Trials

Feb 6, 2018
ORICULA THERAPEUTICS, LLC., a biotech company introducing medications to preserve hearing and balance, announced FDA permission to begin volunteer human testing for safety,…
Read More...
Prev Next
2nd Obesity & Weight Loss Drug Development Summit Europe
RNA-Based Therapeutics & Vaccines Summit South Korea
RNA-Targeted Drug Discovery & Development Summit
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
Neuropsychiatric Drug Development Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Raw Materials for Cell & Gene Therapy Summit
Cell & Gene Therapy Summit South Korea
10th Dermatology Drug Development Summit
9th Lab Asset & Facility Management Summit
TRP Supply Chain & Manufacturing Summit
Covalent Drug Discovery & Development Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • From Innovation to Acquisition: CrossBridge Bio’s ADC Journey
  • COPD Foundations Joins the COPD Drug Development Summit
  • argenx to Acquire Forte Biosciences in $2.2 Billion Deal
  • BioMarin, n-Lorem Join Forces on ReNU Syndrome Therapy
  • Pfizer, Eisai Partner to Co-Promote Nurtec in Japan

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

From Innovation to Acquisition: CrossBridge Bio’s ADC…

COPD Foundations Joins the COPD Drug Development Summit

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.